SAB Biotherapeutics, Inc.

SAB Biotherapeutics, Inc. (Nasdaq: SABS) is a clinical-stage biopharmaceutical company focused on developing fully human polyclonal antibody-based therapies using genetically engineered cattle as a production platform. The company became publicly traded in October 2021 through a merger with Big Rock Partners Acquisition Corp, a blank-check company sponsored by Big Rock Partners LLC. Operating in the biotechnology sector, SAB Biotherapeutics has pursued candidates targeting infectious diseases and immune disorders, with its most advanced programs evaluated in clinical trials. The company filed its most recent annual report on Form 10-K with the SEC on March 9, 2026. For comprehensive deal timelines, clinical-stage metrics, and full SPAC transaction data on SABS, sign up for SpacDesk.